Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 5/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | CDC25A | P30304 | 1/20 | 0.60 |
| ▸ | CDC25C | P30307 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28141853 | 0.92 | RAB9A (0.67) | CDC25BSMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL1170135 | 0.91 | RAB9A (0.65) | CDC25BSMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL27334690 | 0.88 | SMN1; SMN2 (0.62) | CDC25BSMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL28142629 | 0.88 | SMN1; SMN2 (0.59) | CDC25BSMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL9176722 | 0.85 | SMN1; SMN2 (0.72) | SMN1; SMN2RAB9ANPC1KDM4EMAPT | |
| SCHEMBL3627604 | 0.85 | RAB9A (0.58) | CDC25BSMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL6793571 | 0.85 | RAB9A (0.76) | SMN1; SMN2RAB9ANPC1MAPTLMNA | |
| SCHEMBL9937464 | 0.84 | RAB9A (0.61) | CDC25BSMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL584215 | 0.84 | KMT2A (0.65) | CDC25BSMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL1745412 | 0.83 | RAB9A (0.71) | SMN1; SMN2RAB9ANPC1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651888-B1 | N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders | UNIV LEUVEN KATH (BE) | 2017-05-17 | — | — | EP | disclosed |
| CN-103261156-B | For treating the noval chemical compound of neurodegenerative disease | 鲁汶天主教大学研究开发部 | 2016-12-28 | — | — | CN | disclosed |
| US-9266832-B2 | Compounds for the treatment of neurodegenerative diseases | Katholieke Universiteit Levun (BE) | 2016-02-23 | — | — | US | disclosed |
| EP-2651888-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-17 | — | — | US | disclosed |
| CN-103261156-A | New compounds for the treatment of neurodegenerative diseases | LEUVEN K U RES & DEV | 2013-08-21 | — | — | CN | disclosed |
| WO-2012080221-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-21 | — | — | WO | disclosed |
| EP-1485485-A1 | TRANSDIFFERENTIATION OF CELLS AND TISSUES | UNIVERSITY OF BATH (GB) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003078636-A1 | TRANSDIFFERENTIATION OF CELLS AND TISSUES | THE UNIVERSITY OF BATH (GB) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, PSEN1 | CDC25B 1933/4885SMN1; SMN2 12/4885RAB9A 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.